230 related articles for article (PubMed ID: 23475203)
1. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
Li F; Lu J; Cheng J; Wang L; Matsubara T; Csanaky IL; Klaassen CD; Gonzalez FJ; Ma X
Nat Med; 2013 Apr; 19(4):418-20. PubMed ID: 23475203
[TBL] [Abstract][Full Text] [Related]
2. Reparation of Isoniazid and Rifampicin Combinatorial Therapy-Induced Hepatotoxic Effects by Bacopa monnieri.
Evan Prince S; Udhaya LB; Sunitha PS; Arumugam G
Pharmacology; 2016; 98(1-2):29-34. PubMed ID: 27007136
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of anti-tuberculosis therapy induced hepatotoxicity by Spirulina fusiformis, a candidate food supplement.
Martin SJ; Baskaran UL; Vedi M; Sabina EP
Toxicol Mech Methods; 2014 Dec; 24(8):584-92. PubMed ID: 25137345
[TBL] [Abstract][Full Text] [Related]
4. PXR-ALAS1: a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment.
Lyoumi S; Lefebvre T; Karim Z; Gouya L; Puy H
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):439-41. PubMed ID: 23916555
[No Abstract] [Full Text] [Related]
5. Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.
He L; Guo Y; Deng Y; Li C; Zuo C; Peng W
Xenobiotica; 2017 Feb; 47(2):154-163. PubMed ID: 28118809
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
7. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: Evidence of ferroptosis induction.
Pan Y; Tang P; Cao J; Song Q; Zhu L; Ma S; Zhang J
Biochem Biophys Res Commun; 2020 Dec; 533(4):1512-1518. PubMed ID: 33121683
[TBL] [Abstract][Full Text] [Related]
8. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice.
Chen X; Xu J; Zhang C; Yu T; Wang H; Zhao M; Duan ZH; Zhang Y; Xu JM; Xu DX
Eur J Pharmacol; 2011 May; 659(1):53-60. PubMed ID: 21419764
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid-rifampicin induced lipid changes in rats.
Pal R; Rana SV; Vaiphei K; Singh K
Clin Chim Acta; 2008 Mar; 389(1-2):55-60. PubMed ID: 18157944
[TBL] [Abstract][Full Text] [Related]
10. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats.
Yue J; Peng RX; Yang J; Kong R; Liu J
Acta Pharmacol Sin; 2004 May; 25(5):699-704. PubMed ID: 15132840
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity in rifampin-isoniazid treated patients related to their rate of isoniazid inactivation.
Smith J; Tyrell WF; Gow A; Allan GW; Lees AW
Chest; 1972 Jun; 61(6):587-8. PubMed ID: 5032153
[No Abstract] [Full Text] [Related]
12. Hepatoprotective effect of Anacyclus pyrethrum Linn. against antitubercular drug-induced hepatotoxicity in SD rats.
Usmani A; Mujahid M; Khushtar M; Siddiqui HH; Rahman MA
J Complement Integr Med; 2016 Sep; 13(3):295-300. PubMed ID: 27101559
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.
Guo YX; Xu XF; Zhang QZ; Li C; Deng Y; Jiang P; He LY; Peng WX
Toxicol Mech Methods; 2015; 25(5):382-7. PubMed ID: 25886055
[TBL] [Abstract][Full Text] [Related]
14. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
Grönhagen-Riska C; Hellstrom PE; Fröseth B
Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
[TBL] [Abstract][Full Text] [Related]
16. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
Singh J; Garg PK; Thakur VS; Tandon RK
Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
[TBL] [Abstract][Full Text] [Related]
17. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
Bray MG; Poulain C; Dougados M; Gossec L
Joint Bone Spine; 2010 Mar; 77(2):135-41. PubMed ID: 20097592
[TBL] [Abstract][Full Text] [Related]
18. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
[TBL] [Abstract][Full Text] [Related]
19. [Synergistic effect of rifampicin on hepatotoxicity of isoniazid].
Skakun NP; Shman'ko VV
Antibiot Med Biotekhnol; 1985 Mar; 30(3):185-9. PubMed ID: 4015060
[TBL] [Abstract][Full Text] [Related]
20. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
